advanced search

Injectable Drug Delivery: Formulations & Devices133

Issue No #133 May 2022  May 12th, 2022


Download PDF


Inside the magazine

PUTTING PROCESS ENGINEERING INTO ACTION
INJECTION
Jonathan Kearns
SHL Medical
PUTTING PROCESS ENGINEERING INTO ACTION
Jonathan Kearns and Kevin Huang consider how engineering competencies are being driven to the next level by leveraging process engineering and how this can transform drug-device projects.
PREMIUMCOAT<sup>®</sup> SOLUTIONS: HELPING CONTROL THE LEVEL OF SILICONE TO PROTECT SENSITIVE THERAPEUTICS
PREFILLED SYRINGES
Sebastien Cordier
Aptar Pharma
PREMIUMCOAT® SOLUTIONS: HELPING CONTROL THE LEVEL OF SILICONE TO PROTECT SENSITIVE THERAPEUTICS
Sébastien Cordier, Vincent Holterboch and Estelle Verger discuss how coated elastomer components, such as Aptar Pharma’s PremiumCoat®, can help drug developers optimise the balance between component processability and minimising silicone migration into a drug product.
IMPROVING CLINICAL OUTCOMES WITH A PATIENT-CENTRIC AND REUSABLE PEN PLATFORM
INJECTION
Cecile Gross
Nemera
IMPROVING CLINICAL OUTCOMES WITH A PATIENT-CENTRIC AND REUSABLE PEN PLATFORM
Cécile Gross and Radosław Romańczuk discuss Nemera’s Pendura AD pen platform and present case studies demonstrating how it can be tailored to address the user’s needs and meet pharma industry constraints.
INJECTING THE FUTURE
INJECTION
Simone Farina
Flex
INJECTING THE FUTURE
Simone Farina discusses Flex’s new smart autoinjector platform for the healthcare market, designed to enable original equipment manufacturers to accelerate time-to-market, reduce costs and boost reliability, while ensuring patient compliance.
CONNECTED DRUG DELIVERY – MAXIMISING ACCESS BY DESIGN
CONNECTIVITY
Dr Oliver Eden
Jabil Healthcare
CONNECTED DRUG DELIVERY – MAXIMISING ACCESS BY DESIGN
Oliver Eden discusses the factors that drive the design and development of a reusable autoinjector solution. Foremost amongst these considerations is the patient, in terms of ease of use with the device itself and maximising access to the broadest possible population with a versatile, portfolio-enabling platform ready for the connected world.
ADVANCEMENTS AND EVOLUTION OF POWER SOURCES IN DRUG DELIVERY
INJECTION
Bill Welch
Picocyl
ADVANCEMENTS AND EVOLUTION OF POWER SOURCES IN DRUG DELIVERY
William Welch considers the evolution of compressed gas alternatives to spring power for single-use drug delivery devices.
A CHECKLIST FOR AUTOINJECTOR DESIGN
INJECTION
Michael Earl
Owen Mumford
A CHECKLIST FOR AUTOINJECTOR DESIGN
Michael Earl outlines the five key questions autoinjector designers typically ask during the development process and the choices available for tailoring autoinjector products.
EXCELLENCE THROUGH SIMPLICITY: PICCOJECT™ AUTOINJECTOR PLATFORM
INJECTION
Dr Fred Metzmann
Haselmeier
EXCELLENCE THROUGH SIMPLICITY: PICCOJECT™ AUTOINJECTOR PLATFORM
Fred Metzmann and Chris Muenzer discuss the simplicity of the PiccoJect™ autoinjector platform and the company's commitment to sustainability.
Technology Showcase: CCBio’s Felice Dose
WEARABLES
Jimmy Fan
CC Bio
Technology Showcase: CCBio’s Felice Dose
CCBio introduces its wearable (on-body) injector, Felice Dose, which is capable of handling various drug volumes, concentrations and viscosities, as well as different injection speeds and delivery times.
OXYCAPT™: A SUPERIOR PRIMARY CONTAINER MATERIAL FOR BIOLOGICS AND GENE AND CELL THERAPIES
PREFILLED SYRINGES
Hiroki Hasegawa
Mitsubishi Gas Chemical
OXYCAPT™: A SUPERIOR PRIMARY CONTAINER MATERIAL FOR BIOLOGICS AND GENE AND CELL THERAPIES
Hiroki Hasegawa and Tomohiro Suzuki provide an overview of the OXYCAPT multilayer vial and syringe, along with a discussion of how OXYCAPT fares at low and very low temperatures.
EXTRACELLULAR VESICLE ENGINEERING: OPTIMISING NATURE’S NON-IMMUNOGENIC, DRUG DELIVERY PLATFORM
EXPERT VIEW
Dr Anna Cifuentes-Rius
EXTRACELLULAR VESICLE ENGINEERING: OPTIMISING NATURE’S NON-IMMUNOGENIC, DRUG DELIVERY PLATFORM
Anna Cifuentes-Rius discusses the exciting potential of extracellular vesicles to advance drug delivery, in particular their natural ability to carry API payloads across difficult-to-traverse biological barriers.
GLASS-FILLED CELANEX<sup>®</sup> MT<sup>®</sup> PBT HITS SWEET SPOT FOR BIOLOGICS AND REUSABLE DEVICES
INJECTION
Bryan Deacon
Celanese
GLASS-FILLED CELANEX® MT® PBT HITS SWEET SPOT FOR BIOLOGICS AND REUSABLE DEVICES
Bryan Deacon, Marnik Vaes and Peter Burke, introduce a medical-grade glass-filled engineering polymer, Celanex® MT® PBT 2406MT GF20, which fills a gap in the materials market between standard engineering thermoplastics and expensive high-performance polymers.
ENABLING A NEW PARADIGM FOR PEPTIDE DRUG DEVELOPMENT
FORMULATION
Michael Neely
Xeris Pharmaceuticals
ENABLING A NEW PARADIGM FOR PEPTIDE DRUG DEVELOPMENT
 Michael Neely reviews peptide formulations and introduces Xeris's XeriSol™ technology and its potential paradigm-changing capabilities.
RECENT TRENDS & DEVELOPMENTS IN INJECTABLE FORMULATION & DELIVERY
EXPERT VIEW
Dr Martin Gonzalez
RECENT TRENDS & DEVELOPMENTS IN INJECTABLE FORMULATION & DELIVERY
Martin Gonzalez details current trends in sterile injectable formulations and their delivery devices, and the challenges pharma and its contract development and manufacturing company partners face in bringing emerging breakthroughs to market.
INTERVIEW: STEVEN KAUFMAN, STEVANATO GROUP, & MICHAEL EARL, OWEN MUMFORD
INTERVIEW
Steven Kaufman
Stevanato Group
INTERVIEW: STEVEN KAUFMAN, STEVANATO GROUP, & MICHAEL EARL, OWEN MUMFORD
In this exclusive interview, Steven Kaufman of Stevanato Group, and Michael Earl of Owen Mumford, talked with us about their companies' recent major agreement for the manufacturing and provision of prefillable syringes for the advanced two-step, single-use autoinjector, Aidaptus®.
INTERVIEW: AURELIO ARIAS, IQVIA
INTERVIEW
Aurelio Arias
INTERVIEW: AURELIO ARIAS, IQVIA
Aurelio Arias of IQVIA discusses trends in the drug delivery industry, including how device and packaging manufacturers are increasingly aligning as strategic partners to speed innovation and reduce reliance on pharma investment.
Top